A comparative study of effect of epidermal growth factor on chronic leg ulcers with anti-septic dressing


  • Mallikarjuna Reddy M. Department of Surgery, SVS Medical College, Mahabubnagar, Telangana, India
  • Vijayabhaskarreddy Sirigireddy Department of Surgery, SVS Medical College, Mahabubnagar, Telangana, India




EGF, Chronic leg ulcers, Wound dressing


Background: Chronic wounds, particularly non-healing wounds, are one of the most prevalent surgical disorders that a surgeon may see. The characteristic of a chronic wound is that it does not heal despite daily dressings and costly local treatments. Aims of the study to investigate the healing effects of recombinant human epidermal growth factor (hEGF) on non-healing ulcers and to assess the effectiveness, acceptability, and safety of a new epidermal growth factor (EGF) wound dressing.

Methods: On 60 patients with chronic non-healing ulcers, a randomized, prospective, and comparative research was conducted in the department of general surgery, SVS medical college and hospital, Mahbubnagar. These 60 patients were separated into two groups, each with fifteen patients. The EGF was applied to group A, whereas normal saline was given to group B.

Results: The 60 patients who agreed to participate in the trial were separated into two groups (30 each) that were equal and comparable. Patients who received topical EGF 0.01% gel dressings were assigned to the trial, whereas those who received standard antiseptic wound dressing were assigned to the control group. Six of the fifteen patients in the test group were men, whereas eleven were males and four were females in the control group. When the two groups were compared, the test group had a substantial reduction in ulcer area compared to the control group (p<0.001)

Conclusions: EGF is a superior alternative for treating chronic non-healing ulcers because of its cost effectiveness, availability, reduced hospital stay, and simplicity of administration.


Jeter KF, Tintle TE. Wound dressings of the nineties: indications and Contraindications. Clin Plast Surg. 1991;8(4):799-816.

Cohen IK. Lessons from the history of wound healing. Clin Dermatol. 2007;25(1):3-8.

Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366:1736-43.

Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg. 2003;90:133-46.

Dinh T, Braunagel S, Rosenblum BI. Growth factors in wound healing: the present and the future? Clin Podiatr Med Surg. 2015;32:109-19.

Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-62.

Kwon YB, Kim HW, Roh DH, Yoon SY, Baek RM, Kim JY et al. Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat. J Vet Sci. 2006;7:105-9.

Ghatak S, Maytin EV, Mack JA, Hascall VC, Atanelishvili I, Moreno Rodriguez R et al. Roles of proteoglycans and glycosaminoglycans in wound healing and fibrosis. Int J Cell Biol. 2015;2015:834893.

Laato M, Kahari VM, Niinikoski J, Vuorio E. Epidermal growth factor increases collagen production in granulation tissue by stimulation of fibroblast proliferation and not by activation of procollagen genes. Biochem J. 1987;247:385-8.

Brown GL, Curtsinger L, Jurkiewicz MJ, Nahai F, Schultz G. Stimulation of healing of chronic wounds by epidermal growth factor. Plast Reconstr Surg. 1991;88:189-94.

Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair. J Invest Dermatol. 1990;94:624-9.

Shen C, Sun L, Zhu N, Qi F. Kindlin-1 contributes to EGF-induced re-epithelialization in skin wound healing. Int J Mol Med. 2017;39:949-59.

Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg. 2006;56:394-8.

Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26:1856-61.

Park KH, Han SH, Hong JP, Han SK. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial. Diabetic Res Clin Pract. 2018;142:335-4.

Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Perspect Vasc Surg Endovasc Ther. 2012;24:37-44.

Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernandez F et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6:432-43.

Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, Thi Bich DN, Do Dinh T, Le Tan D et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J. 2009;6:159-66.

Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. J Invest Dermatol. 2011;131(1):2121-7.

Vella L, Gatt A, Formosa C. Does baseline hemoglobin A1c level predict diabetic foot ulcer outcome or wound healing time J Am Podiatr Med Assoc. 2017;107:272-9.

Veves A, Falanga V, Armstrong DG, Sabolinski ML. Apligraf Diabetic Foot Ulcer S. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24:290-5.

Prabakar A, Raj RS. Efficacy of recombinant epidermal growth factor in the healing process of diabetic ulcer. J Evol Med Dent Sci. 2016;5(31):1642-8.

Ramachandran V, Rai BR, Rai BR. Epidermal Growth Factor Versus Conventional Wound Dressings in Treatment of Diabetic Ulcers- A Comparative Study. J Dental Med Sci. 2017;16(3):09-15.






Original Research Articles